ClinicalTrials.gg
WithdrawnNCT03355170Updated Jan 5, 2023

Cardiac Safety of Lansoprazole and Domperidon Combination

A Phase 4 interventional study of Lansoprazole/Domperidone and Lansoprazole in GERD, Cardiac Event and Safety Issues, sponsored by Neutec Ar-Ge San ve Tic A.Ş. Withdrawn at 16 sites in Turkey. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-01-05.

Sponsored by Neutec Ar-Ge San ve Tic A.Ş · Phase 4, Interventional, and Screening

Why this study was withdrawn
The sponsor decided to continue with a different design and a different protocol.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.

02

Conditions studied

  • GERD
  • Cardiac Event
  • Safety Issues
03

In context

Gastroesophageal Reflux

1,211 studies on the registry are indexed under Gastroesophageal Reflux; 202 are open to participants now.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Neutec Ar-Ge San ve Tic A.Ş is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • GERD patients with 18-33 kg/m2
  • Patients with esophagitis class A-B according to Los Angeles classification

Exclusion criteria

Exclusion Criteria:

  • Patients whose long syndrome risk score > 3.
  • Patients with family history of short or long QT syndrome.
  • Patients with Barrett's stricture, gastric outlet obstruction, , gastrointestinal system bleeding or any other upper gastrointestinal system pathology.
  • Patients whose Hiatus hernia is > 3 cm.
  • Patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic gallbladder stone, active or unhealed stomach or duodenum ulcer, Zollinger-Ellison syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment, cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy.
  • Patients with history of heart failure, ventricular tachycardia, ventricular fibrillation, cardiac arrest, Torsades de pointes, bradycardia, sinus node dysfunction, heart attack, long QTc (>460 ms).
  • Patients taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before entering the study.
  • Patients with major psychiatric disease.
  • Alcoholism and drug use.
  • Patients with pathologic laboratory tests; hemogram, sedimentation, CRP, thyroid functions tests, liver enzymes.
  • Malabsorption.
  • patients.
  • Patients taken cortisone.
  • Patients taken other drugs that prolong QT interval.
  • Patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents, prostaglandin analogues, sucralfate, atazanavir, theophylline, tacrolimus, fluvoxamine, rifampisin, nefazodone and aprepitant.
  • Patients taken drugs carried with P-glycoprotein, indicated for heart diseases, AIDS/ or infection treatment.
  • Pregnancy or breast-feeding.
  • Patients taken drugs that may affect gastrointestinal system motility or acid release.
  • History of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases may be included; cholecystectomy have to be excluded).
  • Patients with hypocalcemia and hypercalcemia
  • Patients taken NSAII drugs (paracetamol may be used up to 2 gr/day).
  • Patients taken antidepressants.
  • to study drugs.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lansoprazole/Domperidone

    Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.

    Combination Product: Lansoprazole/Domperidone

  • Active comparator
    Lansoprazole

    Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.

    Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Change in QT and corrected QT (QTc) interval compared to baseline

    Time frame: 8 weeks

Secondary outcomes

  1. Change in upper gastrointestinal symptom severity index compared to baseline.

    Time frame: 8 weeks

07

Study locations

16 sites
  • Başkent University Hospital Gastroenterology Dep.
    Adana, Turkey
  • Çukurova University Medical Faculty Cardiology Dep.
    Adana, Turkey
  • Ankara University Medical Faculty Gastroenterology Dep.
    Ankara, Turkey
  • Dışkapı Research and Training Hospital Gastroenterology Dep.
    Ankara, Turkey
  • Yüksek İhtisas Research and Training Hospital Gastroenterology Dep.
    Ankara, Turkey
  • Antalya Research and Training Hospital Gastroenterology Dep.
    Antalya, Turkey
  • Balıkesir University Medical Faculty Gastroenterology Dep.
    Balıkesir, Turkey
  • Gaziantep Şahinbey Research and Training Hospital Gastroenterology Dep.
    Gaziantep, Turkey
  • Dr. Sadi Konuk Research and Training Hospital Gastroenterology Dep.
    Istanbul, Turkey
  • Ümraniye Research and Training Hospital Gastroenterology Dep.
    Istanbul, Turkey
  • Ege University Medical Faculty Gastroenterology Dep.
    İzmir, Turkey
  • Tepecik Research and Training Hospital Gastroenterology Dep.
    İzmir, Turkey
  • Celal Bayar University Medical Faculty Gastroenterology Dep.
    Manisa, Turkey
  • Sıtkı Koçman University Medical Faculty Gastroenterology Dep.
    Muğla, Turkey
  • Recep Tayyip Erdoğan University Medical Faculty Gastroenterology Dep.
    Rize, Turkey
  • Cumhuriyet University Medical Faculty Gastroenterology Dep.
    Sivas, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 28, 2017
StartEst.
Mar 1, 2018
Primary completionActual
Dec 1, 2018
CompletionActual
Jan 1, 2019
Last update
Jan 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03355170
Lead sponsor
Neutec Ar-Ge San ve Tic A.Ş
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Mar 1, 2018 (estimated)
Primary completion
Dec 1, 2018
Completion
Jan 1, 2019
Last update
Jan 5, 2023

Study contacts

Serhat Bor, Prof Dr
study chair · Ege University Medical Faculty Gastroenterology Dep.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lansoprazole · Domperidone

Start the discussion